riluzole has been researched along with Myelopathy in 7 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy using clinical parameters and DTI analysis." | 9.22 | Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial. ( Aiyer, SN; Kanna, RM; Maheswaran, A; Rajasekaran, S; Shetty, AP; Shetty, JY, 2016) |
| "Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery." | 6.80 | Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015) |
| "Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment." | 5.40 | Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014) |
| "To evaluate the effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy using clinical parameters and DTI analysis." | 5.22 | Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial. ( Aiyer, SN; Kanna, RM; Maheswaran, A; Rajasekaran, S; Shetty, AP; Shetty, JY, 2016) |
| "To explain the rationale and design of the cervical spondylotic myelopathy (CSM)-Protect clinical trial that aims to elucidate the efficacy and safety of riluzole in the context of CSM." | 4.89 | Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial. ( Arnold, PM; Fehlings, MG; Karadimas, SK; Kopjar, B; Wilson, JR, 2013) |
| "Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery." | 2.80 | Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015) |
| "Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment." | 1.40 | Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Moghaddamjou, A | 1 |
| Badhiwala, JH | 1 |
| Fehlings, MG | 4 |
| Bartels, RHMA | 1 |
| Kazim, SF | 1 |
| Bowers, CA | 1 |
| Cole, CD | 1 |
| Varela, S | 1 |
| Karimov, Z | 1 |
| Martinez, E | 1 |
| Ogulnick, JV | 1 |
| Schmidt, MH | 1 |
| Wilson, JR | 1 |
| Karadimas, SK | 3 |
| Arnold, PM | 1 |
| Kopjar, B | 1 |
| Moon, ES | 1 |
| Yu, WR | 1 |
| Austin, JW | 1 |
| Rajasekaran, S | 1 |
| Aiyer, SN | 1 |
| Shetty, AP | 1 |
| Kanna, RM | 1 |
| Maheswaran, A | 1 |
| Shetty, JY | 1 |
| Laliberte, AM | 1 |
| Tetreault, L | 1 |
| Chung, YS | 1 |
| Arnold, P | 1 |
| Foltz, WD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Feasibility of Virtual Reality-Based Activities for Upper Limb Rehabilitation of People With Acute/Sub-Acute Tetraplegia[NCT06154122] | 24 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study[NCT01257828] | Phase 3 | 270 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for riluzole and Myelopathy
| Article | Year |
|---|---|
Corticospinal Motor Circuit Plasticity After Spinal Cord Injury: Harnessing Neuroplasticity to Improve Functional Outcomes.
Topics: Animals; Brain-Computer Interfaces; Combined Modality Therapy; Electric Stimulation Therapy; Humans; | 2021 |
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro | 2013 |
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro | 2013 |
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro | 2013 |
Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.
Topics: Cervical Vertebrae; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Neuropro | 2013 |
2 trials available for riluzole and Myelopathy
| Article | Year |
|---|---|
Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial.
Topics: Diffusion Tensor Imaging; Double-Blind Method; Female; Humans; Male; Neuroprotective Agents; Riluzol | 2016 |
Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy.
Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magneti | 2015 |
3 other studies available for riluzole and Myelopathy
| Article | Year |
|---|---|
Degenerative Cervical Myelopathy: Changing Frontiers.
Topics: Cell- and Tissue-Based Therapy; Cervical Vertebrae; Excitatory Amino Acid Antagonists; Genetic Thera | 2020 |
A new dimension in degenerative cervical myelopathy.
Topics: Cervical Vertebrae; Double-Blind Method; Humans; Riluzole; Spinal Cord Diseases | 2021 |
Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Gait; Hyperalgesia; Neur | 2014 |